-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

653.O1.6 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Phase 2 and 3 Trials in Myeloma

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Clinical Trials, Clinical Research, Plasma Cell Disorders, Diseases, Therapies, Lymphoid Malignancies
Saturday, December 11, 2021: 9:30 AM-11:00 AM
Hall C1 (Georgia World Congress Center)
Moderators:
Xavier Leleu, MD, Service D'Hématologie Et Thérapie Cellulaire and Ciara L. Freeman, MD PhD MSc, Moffitt Cancer Center & Research Institute
Disclosures:
No relevant conflicts of interest to declare.
Phase 2 and 3 Trials in MM
9:30 AM

Jacob P. Laubach1*, Jonathan L. Kaufman, MD2, Douglas W. Sborov, MD, MSc3, Brandi Reeves, MD4, Cesar Rodriguez5, Ajai Chari, MD6*, Rebecca W. Silbermann, MD7, Luciano J. Costa, MD, PhD8, Larry D. Anderson Jr., MD, PhD9, Nitya Nathwani, MD10, Nina Shah, MD11, Naresh Bumma, MD12, Yvonne A. Efebera, MD, MPH13, Sarah A. Holstein, MD, PhD14, Caitlin Costello, MD15, Andrzej Jakubowiak16, Tanya M. Wildes, MD, MSc17, Robert Z. Orlowski18, Kenneth H. Shain, MD, PhD19, Andrew J. Cowan20*, Huiling Pei, PhD21*, Annelore Cortoos22*, Sharmila Patel, PhD22*, J Blake Bartlett, PhD23, Jessica Vermeulen24, Thomas S. Lin, MD, PhD22, Paul G. Richardson, MD25 and Peter M. Voorhees, MD26*

1Dana-Farber Cancer Institute, Boston, MA
2Winship Cancer Institute, Emory University, Atlanta, GA
3Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
4University of North Carolina – Chapel Hill, Chapel Hill, NC
5Wake Forest University School of Medicine, Winston-Salem, NC
6Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY
7Knight Cancer Institute, Oregon Health & Science University, Portland, OR
8University of Alabama at Birmingham, Birmingham, AL
9Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX
10Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA
11Department of Medicine, University of California San Francisco, San Francisco, CA
12Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
13OhioHealth, Columbus, OH
14Division of Oncology & Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
15Moores Cancer Center, University of California San Diego, La Jolla, CA
16University of Chicago Medical Center, Chicago, IL
17Cancer & Aging Research Group, St. Louis, MO
18Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
19Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
20Division of Medical Oncology, University of Washington, Seattle, WA
21Janssen Research & Development, LLC, Titusville, NJ
22Janssen Scientific Affairs, LLC, Horsham, PA
23Janssen Research & Development, LLC, Raritan, NJ
24Janssen Research & Development, Leiden, Netherlands
25Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
26Levine Cancer Institute - Atrium Health, Charlotte, NC

9:45 AM

Kaz Groen1*, Claudia A.M. Stege, MD2*, Kazem Nasserinejad, PhD3*, Koen de Heer, MD, PhD4*, Roel J.W. Van Kampen, MD, PhD5, Maria B.L. Leijs, MD6*, Noortje Thielen, MD, PhD7*, Matthijs Westerman, MD8*, Ka Lung Wu, MD9, Inge Ludwig, MD, MSc10*, Djamila Issa11*, Gerjo A. Velders, PhD, MD12*, Marie-Christiane Vekemans13*, Niels W.C.J. van de Donk14, Gert-Jan Timmers15*, Pieter Sonneveld16, Maarten R. Seefat, MD17*, Fransien Croon-de Boer18*, Lidwine W. Tick, MD, PhD19, Ellen van der Spek, MD, PhD20*, Esther G.M. De Waal, MD21*, Maaike Sohne, MD22*, Paula F Ypma, MD, PhD23*, Inger S. Nijhof, MD, PhD24*, Saskia K. Klein, MD, PhD25,26, Mark-David Levin, MD, PhD27 and Sonja Zweegman28

1Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, NLD
2Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands
3HOVON data center, Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
4Department of Internal Medicine, Flevoziekenhuis, Almere, Netherlands
5Zuyderland Medical Center, Sittard-Geleen, NLD
6Maasstad Ziekenhuis, Rotterdam, Netherlands
7Department of Internal Medicine, Diakonessenziekenhuis, Utrecht, NLD
8Northwest Clinics, Alkmaar, NLD
9Department of Hematology, Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium
10Department of Hematologie, Bernhoven Hospital, Uden, NLD
11Jeroen Bosch Hospital, Den Bosch, NLD
12Department of Internal Medicine, Gelderse Vallei Hospital, Ede, Netherlands
13Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Bruxelles, Belgium
14Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands
15Amstelland Hospital, Amstelveen, NLD
16Erasmus MC University and Medical Center, Rotterdam, Netherlands
17Department of Hematology, Amsterdam UMC, Amsterdam, Netherlands
18Ikazia Hospital, Rotterdam, Netherlands
19Maxima Medical Center, Veldhoven, NLD
20Department of Internal Medicine, Rijnstate Hospital, Arnhem, Netherlands
21Oncologisch Centrum Leeuwarden, Medisch Centrum Leeuwarden, Leeuwarden, Netherlands
22Department of Internal Medicine/Hematology, Antonius Ziekenhuis, Nieuwegein, NLD
23Haga Hospital, The Hague, Netherlands
24Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands
25Meander Medical Center, Amersfoort, Netherlands
26University Medical Center Groningen, Groningen, Netherlands
27Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands
28VUMC, Amsterdam, Netherlands

10:00 AM

Gordon Cook, MD1,2*, Charlotte Pawlyn, BA, MB BChir, PhD, MRCP, FRCPath3,4, Kara-Louise Royle, MSc2*, Amy Beth Coulson, MSc2*, Jennifer Bird, MBBS, MRCP5*, Stella Bowcock, MD, BA, FRCP, FRCPath, MA6,7*, Matthew W Jenner8*, Bhuvan Kishore, MD9*, Christopher Parrish, MD10, Neil K Rabin, MD, PhD11*, Phillip Best2*, Sharon Gillson2*, Rowena Henderson2*, Catherine Olivier2*, Martin F. Kaiser, MD, FRCP, FRCPath3, Ruth M. de Tute, PhD, FRCPath12*, Roger G Owen, MD12*, Mark T Drayson, MD13*, John R Jones, MD7,14,15*, Bryony Dawkins, BA, MSc16*, David Meads, Ba, MSc, PhD16*, David Cairns, PhD2* and Graham Jackson, MBBS, FRCP, FRCPath, MA, DM17

1Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
2Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
3The Institute of Cancer Research, London, United Kingdom
4The Royal Marsden NHS Foundation Trust, London, United Kingdom
5Department of Haematology, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
6Queen Mary's Sidcup NHS Trust, Sidcup, United Kingdom
7King's College Hospital NHS Foundation Trust, London, United Kingdom
8Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
9University Hospitals Birmingham NHS Foundation Trust, WMRC, Birmingham, United Kingdom
10Leeds Teaching Hospitals NHS Trust, Leeds, ENG, United Kingdom
11Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
12HMDS, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
13Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
14Eastbourne District General Hospital, Eastbourne, United Kingdom
15Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom
16Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom
17Department of Haematology, University of Newcastle, Newcastle upon Tyne, United Kingdom

10:15 AM

Magaret Macro1*, Cyrille Touzeau, MD, PhD2*, Clara Mariette, MD3*, Salomon Manier, MD, PhD4,5, Sabine Brechignac, MD6*, Laure Vincent, MD7*, Benjamin Hebraud, MD8*, Olivier Decaux, MD, PhD9*, Samantha Schulmann, MD10*, Caroline Bureau Lenoir, MD11*, Pascal Godmer, MD12*, Jean-Jacques Parienti, MD, PHD13* and Xavier Leleu, MD14

1Institut d’Hématologie de Basse Normandie, Centre Hospitalier et Universitaire de Caen, Caen, France
2Hématologie Clinique CHU Hôtel Dieu, University Hospital, Nantes, France
3Service d'Hématologie, CHU de Grenoble, Grenoble, France
4University of Lille, INSERM UMRS1277, CNRS UMR9020, Lille, MA, France
5Service des Maladies du Sang, CHU Lille, Lille, France
6Hematology, Avicenne Hospital, APHP, University Paris XIII, Bobigny, France
7CHU de Montpellier / Département d'hématologie clinique, Hôpital Saint-Eloi, Montpellier, France
8Institut Universitaire du Cancer and University Hospital, Toulouse, France
9Service d'Hématologie, CHU de Rennes, Rennes, France
10Service d'Hématologie, CHRU Nancy, University Hospital, Nancy, France
11Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France
12Clinical Hematology, Centre Hospitalier Bretagne Atlantique, Vannes, France
13Unité de recherche clinique, Hospital University Caen, Caen, France
14Service D'Hématologie Et Thérapie Cellulaire, Poitiers, France

10:30 AM

Shaji K Kumar, MD1, Simon J Harrison, MD2, Michele Cavo, MD, PhD3*, Javier de la Rubia, MD, PhD4*, Rakesh Popat, MBBS, FRCPath, PhD5*, Cristina J. Gasparetto, MD6*, Vania Hungria7, Hans Salwender, MD8*, Kenshi Suzuki, MD, PhD9, Inho Kim, MD, PhD10*, Maika Onishi, MD, MAS11, Grace Ku, MD11*, Rajvineeth Kumar Pothacamury, MD12*, Vasudha Sehgal, PhD12*, Abdullah A. Masud, PhD12*, Jeremy A. Ross, PhD12*, Edyta Dobkowska, MD13* and Philippe Moreau, MD, PhD14*

1Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
2Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia
3IRCCS Azienda Ospedaliero Universitaria di Bologna, Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
4Hematology Service Hospital La Fe and School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain
5University College London Hospitals, NHS Foundation Trust, London, United Kingdom
6Duke University Medical Center, Durham, NC
7Clinica São Germano, São Paulo, Brazil
8Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg, Germany
9Department of Hematology, Japanese Red Cross Central Medical Center, Tokyo, Japan
10Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
11Genentech, Inc., South San Francisco, CA
12AbbVie Inc., North Chicago, IL
13Pharmacyclics Switzerland GmbH, An AbbVie Company, Schaffhausen, Switzerland
14University Hospital Hôtel-Dieu, Nantes, Nantes, France

10:45 AM

Herve Avet Loiseau, MD, PhD1, Pieter Sonneveld2, Philippe Moreau, MD, PhD3*, Fritz Offner, MD, PhD4, Vincent H.J. van der Velden, PhD5*, Denis Caillot, MD6*, Cyrille Hulin7*, Bertrand Arnulf, MD8*, Jill Corre1*, Mohamad Mohty, MD, PhD9, Lionel Karlin10*, Jérôme Lambert, MD, PhD11*, Margaret Macro12*, Aurore Perrot13*, Mark-David Levin, MD, PhD14, Saskia K. Klein, MD, PhD15*, Anne-Marie Stoppa16*, Michel Delforge17*, Sonja Zweegman18, Kon-Siong Jie, MD19, Niels W.C.J. Van De Donk20, Maria Krevvata, PhD21*, Fabio Rigat22*, Shiyi Yang21*, Veronique Vanquickelberghe23*, Carla de Boer24*, Tobias Kampfenkel24, Jessica Vermeulen24, Soraya Wuillème, PharmD, PhD25*, Annemiek Broyl26* and Marie C Bene, PharmD, DPhil25*

1Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France
2Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands
3Hematology, University Hospital Hôtel-Dieu, Nantes, France
4Hematology, University Hospital Ghent, Gent, Belgium
5Department of Immunology, Erasmus MC, Rotterdam, Netherlands
6CHU Dijon, Hôpital Du Bocage, Dijon, France
7Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France
8Immuno-Hématologie, Hopital Saint Louis, APHP, Paris, France
9Hospital Saint-Antoine, Sorbonne University, Paris, France
10Department of Hematology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France
11Biostatistical Department, Hôpital Saint Louis, Paris, France
12Centre Hospitalier Universitaire (CHU) de Caen, Caen, France
13CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France
14Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands
15Department of Hematology, University Medical Center Groningen, Groningen, Netherlands
16Institut Paoli Calmettes, Marseille, France
17Universitaire Ziekenhuizen Leuven, Leuven, Belgium
18Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Department of Hematology, Amsterdam, Netherlands
19Zuyderland MC, Sittard, Netherlands
20Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
21Janssen Research & Development, LLC, Spring House, PA
22Janssen-Cilag Limited, High Wycombe, United Kingdom
23Janssen Research & Development, LLC, Beerse, Belgium
24Janssen Research & Development, LLC, Leiden, Netherlands
25Hematology Biology, University Hospital Hôtel Dieu, Nantes, France
26Erasmus MC Cancer Institute, Rotterdam, Netherlands

*signifies non-member of ASH